Phase II Study of Elranatamab in Outpatients with Relapsed/Refractory Multiple Myeloma
The study aims to assess the incidence of cytokine release syndrome during the first treatment cycle of elranatamab in RRMM patients.
Asset / Drug
Drug and asset intelligence for Elranatamab with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.